A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Recruiting

Phase 1

Phase 2

ALD-102A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

Sponsor:

Aldena Therapeutics

Code:

NCT06826196

Conditions

Alopecia Areata (AA)

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

ALD-102 Solution

Placebo or Control

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-28. This information was provided to ClinicalTrials.gov by Aldena Therapeutics on 2026-03-04.